EuropeFX has recently expanded its own offering to include a basket of seven Pharma Stocks.
FM
2020 has been defined by the outbreak of Covid-19, which according to many health experts has yet to even reach its peak.
To date, a vaccine has not yet been created to combat the virus, though pharmaceutical companies worldwide are aggressively pursuing one.
This has made investing in pharmaceutical stocks one of the most attractive options in 2020, given the huge potential upside of rolling out the first vaccine for Covid-19.
EuropeFX is clearly cognizant of this demand, having recently expanded its own offering to include a basket of Pharma Stocks.
The brokerage is now offering exposure into seven different pharmaceutical companies that are currently the frontrunners for a Covid-19 vaccine.
Why Now Could Be an Interesting Time to Invest in Pharma Stocks
Hundreds of thousands have died worldwide and the demand for a vaccine has never been higher. This has created an unprecedented demand, which could catapult a pharmaceutical’s valuation through the roof overnight.
Traditionally, pharmaceutical companies face long roads to inventing vaccines. Long before these get to the market, a vaccine has to pass multiple stages of trials to ensure its safety.
These are decreased, however, once the World Health Organization (WHO) has announced a pandemic, which is the case for Covid-19.
As a result, several pharmaceutical companies have seen an extraordinary level of speculative interest from investors during the trial stages of a vaccine.
Which Companies Could You Invest in?
EuropeFX now has seven pharmaceutical companies leading the race for a Covid-19 vaccine globally on offer. This includes the following companies:
Gilead Sciences Inc.
(NASDAQ:GILD)
A research-based biopharmaceutical company, Gilead Sciences, currently carries over twenty-five marketed treatments in the United States for HIV and Aids, Liver Diseases, Hematology and Oncology, Cardiovascular Disease and Inflammation and Respiratory Disease. Gilead is currently in Phase-3 trials for Remdesivir, a Covid-19 drug.
Merck KGaA
(NYSE:MRK)
Founded in Darmstadt, Germany, Merck & Co is active in sixty-six countries and with around 57,000 employees, the Company generated sales of €16.2 billion in 2019. The Company is active in all areas of pharmaceutical production and food safety and is heavily involved in the performance material sector for a broad and diverse range of industries.
Amgen Inc.
(NASDAQ:AMGN)
Founded in the United States in 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies. Amgen is currently focused on six therapeutic areas: cardiovascular disease, oncology, bone health, neuroscience, nephrology, and inflammation. The Company generated sales of $22.2 billion in 2019.
Dynavax Technologies Inc.
(NASDAQ:DVAX)
Dynavax Technologies Corporation develops and commercializes novel vaccines. The Company’s first commercial product, HEPLISAV-B [Hepatitis B Vaccine (Recombinant), Adjuvanted], a hepatitis B vaccine for adults, is approved in the United States. 2019 saw product revenue of $34.6 million.
Biogen Inc.
(NASDAQ:BIIB)
Founded in Geneva, Switzerland, Biogen helped pioneer the biotechnology industry. A leader in the development of treatments for Multiple Sclerosis, Spinal Muscular Atrophy, and Alzheimer’s Disease, Biogen’s revenues in 2019 were over $14.3 billion, for a 4.5% increase in total revenues year over year.
Biotest Aktiengesellschaft
(XETRA:BIO3.DE)
Founded in Germany, Biotest markets different products in three therapeutic areas: clinical immunology, haematology, and intensive care medicine. The Company is active globally, with locations in Europe, South America, and the Russian Federation. 2019 saw revenues of over €419 million, and the Company embarked on an ambitious expansion program with investments of over €300 million planned for their Dreieich location with the creation of over 300 new jobs in the region.
Moderna, Inc
(NASDAQ:MRNA)
Moderna, Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases.
Risk Warning: CFDs are complex instruments and carry a high risk of losing money quickly due to leverage. 78.94% of retail investor accounts lose money when trading CFDs with this provider. The information contained in this market overview should in no way be construed as investment advice and/or as a proposal and/or request for trading activities and financial transactions. The data contained in this market overview is not necessarily real-time or error-free. The data and prices on the material are not necessarily provided by a market or exchange, but by market makers, so that prices may not be accurate and may differ from the actual price in a particular market, meaning that prices are indicative and not suitable for trading purposes. There is no guarantee and/or prediction of future performance. EuropeFX, its affiliates, agents, directors or employees do not guarantee the accuracy or validity of any information or data provided and shall not be liable for any loss arising from any investment based thereon. Trading Forex/CFD's carries a high level of risk and may result in the loss of your entire investment. Forex/CFD's are leveraged products and therefore trading Forex/CFD's may not be suitable for all investors. It is recommended not to invest more money than you can afford to lose in order to avoid significant financial problems in case of losses. Please make sure that you define the maximum risk for yourself.
2020 has been defined by the outbreak of Covid-19, which according to many health experts has yet to even reach its peak.
To date, a vaccine has not yet been created to combat the virus, though pharmaceutical companies worldwide are aggressively pursuing one.
This has made investing in pharmaceutical stocks one of the most attractive options in 2020, given the huge potential upside of rolling out the first vaccine for Covid-19.
EuropeFX is clearly cognizant of this demand, having recently expanded its own offering to include a basket of Pharma Stocks.
The brokerage is now offering exposure into seven different pharmaceutical companies that are currently the frontrunners for a Covid-19 vaccine.
Why Now Could Be an Interesting Time to Invest in Pharma Stocks
Hundreds of thousands have died worldwide and the demand for a vaccine has never been higher. This has created an unprecedented demand, which could catapult a pharmaceutical’s valuation through the roof overnight.
Traditionally, pharmaceutical companies face long roads to inventing vaccines. Long before these get to the market, a vaccine has to pass multiple stages of trials to ensure its safety.
These are decreased, however, once the World Health Organization (WHO) has announced a pandemic, which is the case for Covid-19.
As a result, several pharmaceutical companies have seen an extraordinary level of speculative interest from investors during the trial stages of a vaccine.
Which Companies Could You Invest in?
EuropeFX now has seven pharmaceutical companies leading the race for a Covid-19 vaccine globally on offer. This includes the following companies:
Gilead Sciences Inc.
(NASDAQ:GILD)
A research-based biopharmaceutical company, Gilead Sciences, currently carries over twenty-five marketed treatments in the United States for HIV and Aids, Liver Diseases, Hematology and Oncology, Cardiovascular Disease and Inflammation and Respiratory Disease. Gilead is currently in Phase-3 trials for Remdesivir, a Covid-19 drug.
Merck KGaA
(NYSE:MRK)
Founded in Darmstadt, Germany, Merck & Co is active in sixty-six countries and with around 57,000 employees, the Company generated sales of €16.2 billion in 2019. The Company is active in all areas of pharmaceutical production and food safety and is heavily involved in the performance material sector for a broad and diverse range of industries.
Amgen Inc.
(NASDAQ:AMGN)
Founded in the United States in 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies. Amgen is currently focused on six therapeutic areas: cardiovascular disease, oncology, bone health, neuroscience, nephrology, and inflammation. The Company generated sales of $22.2 billion in 2019.
Dynavax Technologies Inc.
(NASDAQ:DVAX)
Dynavax Technologies Corporation develops and commercializes novel vaccines. The Company’s first commercial product, HEPLISAV-B [Hepatitis B Vaccine (Recombinant), Adjuvanted], a hepatitis B vaccine for adults, is approved in the United States. 2019 saw product revenue of $34.6 million.
Biogen Inc.
(NASDAQ:BIIB)
Founded in Geneva, Switzerland, Biogen helped pioneer the biotechnology industry. A leader in the development of treatments for Multiple Sclerosis, Spinal Muscular Atrophy, and Alzheimer’s Disease, Biogen’s revenues in 2019 were over $14.3 billion, for a 4.5% increase in total revenues year over year.
Biotest Aktiengesellschaft
(XETRA:BIO3.DE)
Founded in Germany, Biotest markets different products in three therapeutic areas: clinical immunology, haematology, and intensive care medicine. The Company is active globally, with locations in Europe, South America, and the Russian Federation. 2019 saw revenues of over €419 million, and the Company embarked on an ambitious expansion program with investments of over €300 million planned for their Dreieich location with the creation of over 300 new jobs in the region.
Moderna, Inc
(NASDAQ:MRNA)
Moderna, Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases.
Risk Warning: CFDs are complex instruments and carry a high risk of losing money quickly due to leverage. 78.94% of retail investor accounts lose money when trading CFDs with this provider. The information contained in this market overview should in no way be construed as investment advice and/or as a proposal and/or request for trading activities and financial transactions. The data contained in this market overview is not necessarily real-time or error-free. The data and prices on the material are not necessarily provided by a market or exchange, but by market makers, so that prices may not be accurate and may differ from the actual price in a particular market, meaning that prices are indicative and not suitable for trading purposes. There is no guarantee and/or prediction of future performance. EuropeFX, its affiliates, agents, directors or employees do not guarantee the accuracy or validity of any information or data provided and shall not be liable for any loss arising from any investment based thereon. Trading Forex/CFD's carries a high level of risk and may result in the loss of your entire investment. Forex/CFD's are leveraged products and therefore trading Forex/CFD's may not be suitable for all investors. It is recommended not to invest more money than you can afford to lose in order to avoid significant financial problems in case of losses. Please make sure that you define the maximum risk for yourself.
INFINOX rebrands around a provocative idea: Trading is not for everyone
Featured Videos
Trade Republic Account Switch; eToro and Alpaca Get SEC Relief
Trade Republic Account Switch; eToro and Alpaca Get SEC Relief
Trade Republic Account Switch; eToro and Alpaca Get SEC Relief
Trade Republic Account Switch; eToro and Alpaca Get SEC Relief
Today’s financial news recap covers Trade Republic gives some Portuguese clients two days to switch accounts, eToro and Alpaca receive SEC relief, the ECB launches Pontes, and Revolut outlines its low-lending banking model.
Finance Magnates Daily Recap brings you the latest news from forex and CFD brokers, fintech, payments, cryptocurrency, digital assets, trading platforms, financial regulation and global markets.
Get the key company news, executive moves, deals, regulatory updates and market developments of the day, in just a few minutes. New episodes published every weekday.
Read more: https://www.financemagnates.com
#FinanceMagnates #ForexNews #FintechNews
Today’s financial news recap covers Trade Republic gives some Portuguese clients two days to switch accounts, eToro and Alpaca receive SEC relief, the ECB launches Pontes, and Revolut outlines its low-lending banking model.
Finance Magnates Daily Recap brings you the latest news from forex and CFD brokers, fintech, payments, cryptocurrency, digital assets, trading platforms, financial regulation and global markets.
Get the key company news, executive moves, deals, regulatory updates and market developments of the day, in just a few minutes. New episodes published every weekday.
Read more: https://www.financemagnates.com
#FinanceMagnates #ForexNews #FintechNews
Today’s financial news recap covers Trade Republic gives some Portuguese clients two days to switch accounts, eToro and Alpaca receive SEC relief, the ECB launches Pontes, and Revolut outlines its low-lending banking model.
Finance Magnates Daily Recap brings you the latest news from forex and CFD brokers, fintech, payments, cryptocurrency, digital assets, trading platforms, financial regulation and global markets.
Get the key company news, executive moves, deals, regulatory updates and market developments of the day, in just a few minutes. New episodes published every weekday.
Read more: https://www.financemagnates.com
#FinanceMagnates #ForexNews #FintechNews
Today’s financial news recap covers Trade Republic gives some Portuguese clients two days to switch accounts, eToro and Alpaca receive SEC relief, the ECB launches Pontes, and Revolut outlines its low-lending banking model.
Finance Magnates Daily Recap brings you the latest news from forex and CFD brokers, fintech, payments, cryptocurrency, digital assets, trading platforms, financial regulation and global markets.
Get the key company news, executive moves, deals, regulatory updates and market developments of the day, in just a few minutes. New episodes published every weekday.
Read more: https://www.financemagnates.com
#FinanceMagnates #ForexNews #FintechNews
Why Companies Struggle to Turn Strategy into Action | Simon Andras | Simon Says Mindset
Why Companies Struggle to Turn Strategy into Action | Simon Andras | Simon Says Mindset
Why Companies Struggle to Turn Strategy into Action | Simon Andras | Simon Says Mindset
Why Companies Struggle to Turn Strategy into Action | Simon Andras | Simon Says Mindset
Why Companies Struggle to Turn Strategy into Action | Simon Andras | Simon Says Mindset
Why Companies Struggle to Turn Strategy into Action | Simon Andras | Simon Says Mindset
Why do companies struggle to turn their goals into actual results? In this studio interview, Simon Andras, Co-Founder of Simon Says Mindset, discusses his consultancy and how it helps companies identify the structural, communication, leadership, and performance issues holding them back.
Simon explains why third-party diagnosis can help uncover structural, communication, leadership, and performance issues, and why long-term change matters more than short-term motivation.
In this interview, you'll learn:
Why companies struggle to turn goals into action
How leadership and communication issues affect performance
Why delegation is essential for developing future leaders
How Simon Says Mindset approaches company diagnosis
Why traditional training and short-term motivation aren't enough
Simon's take on common business practices, from annual reviews to promoting top salespeople into management
#Leadership #BusinessConsulting #Management #BusinessStrategy #Fintech #FinanceMagnates
Why do companies struggle to turn their goals into actual results? In this studio interview, Simon Andras, Co-Founder of Simon Says Mindset, discusses his consultancy and how it helps companies identify the structural, communication, leadership, and performance issues holding them back.
Simon explains why third-party diagnosis can help uncover structural, communication, leadership, and performance issues, and why long-term change matters more than short-term motivation.
In this interview, you'll learn:
Why companies struggle to turn goals into action
How leadership and communication issues affect performance
Why delegation is essential for developing future leaders
How Simon Says Mindset approaches company diagnosis
Why traditional training and short-term motivation aren't enough
Simon's take on common business practices, from annual reviews to promoting top salespeople into management
#Leadership #BusinessConsulting #Management #BusinessStrategy #Fintech #FinanceMagnates
Why do companies struggle to turn their goals into actual results? In this studio interview, Simon Andras, Co-Founder of Simon Says Mindset, discusses his consultancy and how it helps companies identify the structural, communication, leadership, and performance issues holding them back.
Simon explains why third-party diagnosis can help uncover structural, communication, leadership, and performance issues, and why long-term change matters more than short-term motivation.
In this interview, you'll learn:
Why companies struggle to turn goals into action
How leadership and communication issues affect performance
Why delegation is essential for developing future leaders
How Simon Says Mindset approaches company diagnosis
Why traditional training and short-term motivation aren't enough
Simon's take on common business practices, from annual reviews to promoting top salespeople into management
#Leadership #BusinessConsulting #Management #BusinessStrategy #Fintech #FinanceMagnates
Why do companies struggle to turn their goals into actual results? In this studio interview, Simon Andras, Co-Founder of Simon Says Mindset, discusses his consultancy and how it helps companies identify the structural, communication, leadership, and performance issues holding them back.
Simon explains why third-party diagnosis can help uncover structural, communication, leadership, and performance issues, and why long-term change matters more than short-term motivation.
In this interview, you'll learn:
Why companies struggle to turn goals into action
How leadership and communication issues affect performance
Why delegation is essential for developing future leaders
How Simon Says Mindset approaches company diagnosis
Why traditional training and short-term motivation aren't enough
Simon's take on common business practices, from annual reviews to promoting top salespeople into management
#Leadership #BusinessConsulting #Management #BusinessStrategy #Fintech #FinanceMagnates
Why do companies struggle to turn their goals into actual results? In this studio interview, Simon Andras, Co-Founder of Simon Says Mindset, discusses his consultancy and how it helps companies identify the structural, communication, leadership, and performance issues holding them back.
Simon explains why third-party diagnosis can help uncover structural, communication, leadership, and performance issues, and why long-term change matters more than short-term motivation.
In this interview, you'll learn:
Why companies struggle to turn goals into action
How leadership and communication issues affect performance
Why delegation is essential for developing future leaders
How Simon Says Mindset approaches company diagnosis
Why traditional training and short-term motivation aren't enough
Simon's take on common business practices, from annual reviews to promoting top salespeople into management
#Leadership #BusinessConsulting #Management #BusinessStrategy #Fintech #FinanceMagnates
Why do companies struggle to turn their goals into actual results? In this studio interview, Simon Andras, Co-Founder of Simon Says Mindset, discusses his consultancy and how it helps companies identify the structural, communication, leadership, and performance issues holding them back.
Simon explains why third-party diagnosis can help uncover structural, communication, leadership, and performance issues, and why long-term change matters more than short-term motivation.
In this interview, you'll learn:
Why companies struggle to turn goals into action
How leadership and communication issues affect performance
Why delegation is essential for developing future leaders
How Simon Says Mindset approaches company diagnosis
Why traditional training and short-term motivation aren't enough
Simon's take on common business practices, from annual reviews to promoting top salespeople into management
#Leadership #BusinessConsulting #Management #BusinessStrategy #Fintech #FinanceMagnates
Revolut Reconsiders London Listing; NAGA CEO on Return to Profit
Revolut Reconsiders London Listing; NAGA CEO on Return to Profit
Revolut Reconsiders London Listing; NAGA CEO on Return to Profit
Revolut Reconsiders London Listing; NAGA CEO on Return to Profit
Revolut Reconsiders London Listing; NAGA CEO on Return to Profit
Revolut Reconsiders London Listing; NAGA CEO on Return to Profit
Today’s financial news recap covers NAGA CEO discusses its return to profitability, Revolut reconsiders a London listing, Warren Buffett is stepping down as chairman and the FCA targets illegal peer-to-peer crypto sites.
Finance Magnates Daily Recap brings you the latest news from forex and CFD brokers, fintech, payments, cryptocurrency, digital assets, trading platforms, financial regulation and global markets.
Get the key company news, executive moves, deals, regulatory updates and market developments of the day, in just a few minutes. New episodes published every weekday.
Read more: https://www.financemagnates.com
#FinanceMagnates #ForexNews #FintechNews
Today’s financial news recap covers NAGA CEO discusses its return to profitability, Revolut reconsiders a London listing, Warren Buffett is stepping down as chairman and the FCA targets illegal peer-to-peer crypto sites.
Finance Magnates Daily Recap brings you the latest news from forex and CFD brokers, fintech, payments, cryptocurrency, digital assets, trading platforms, financial regulation and global markets.
Get the key company news, executive moves, deals, regulatory updates and market developments of the day, in just a few minutes. New episodes published every weekday.
Read more: https://www.financemagnates.com
#FinanceMagnates #ForexNews #FintechNews
Today’s financial news recap covers NAGA CEO discusses its return to profitability, Revolut reconsiders a London listing, Warren Buffett is stepping down as chairman and the FCA targets illegal peer-to-peer crypto sites.
Finance Magnates Daily Recap brings you the latest news from forex and CFD brokers, fintech, payments, cryptocurrency, digital assets, trading platforms, financial regulation and global markets.
Get the key company news, executive moves, deals, regulatory updates and market developments of the day, in just a few minutes. New episodes published every weekday.
Read more: https://www.financemagnates.com
#FinanceMagnates #ForexNews #FintechNews
Today’s financial news recap covers NAGA CEO discusses its return to profitability, Revolut reconsiders a London listing, Warren Buffett is stepping down as chairman and the FCA targets illegal peer-to-peer crypto sites.
Finance Magnates Daily Recap brings you the latest news from forex and CFD brokers, fintech, payments, cryptocurrency, digital assets, trading platforms, financial regulation and global markets.
Get the key company news, executive moves, deals, regulatory updates and market developments of the day, in just a few minutes. New episodes published every weekday.
Read more: https://www.financemagnates.com
#FinanceMagnates #ForexNews #FintechNews
Today’s financial news recap covers NAGA CEO discusses its return to profitability, Revolut reconsiders a London listing, Warren Buffett is stepping down as chairman and the FCA targets illegal peer-to-peer crypto sites.
Finance Magnates Daily Recap brings you the latest news from forex and CFD brokers, fintech, payments, cryptocurrency, digital assets, trading platforms, financial regulation and global markets.
Get the key company news, executive moves, deals, regulatory updates and market developments of the day, in just a few minutes. New episodes published every weekday.
Read more: https://www.financemagnates.com
#FinanceMagnates #ForexNews #FintechNews
Today’s financial news recap covers NAGA CEO discusses its return to profitability, Revolut reconsiders a London listing, Warren Buffett is stepping down as chairman and the FCA targets illegal peer-to-peer crypto sites.
Finance Magnates Daily Recap brings you the latest news from forex and CFD brokers, fintech, payments, cryptocurrency, digital assets, trading platforms, financial regulation and global markets.
Get the key company news, executive moves, deals, regulatory updates and market developments of the day, in just a few minutes. New episodes published every weekday.
Read more: https://www.financemagnates.com
#FinanceMagnates #ForexNews #FintechNews
iFOREX Revises Earnings Forecast; AvaTrade to Close Polish Office
iFOREX Revises Earnings Forecast; AvaTrade to Close Polish Office
iFOREX Revises Earnings Forecast; AvaTrade to Close Polish Office
iFOREX Revises Earnings Forecast; AvaTrade to Close Polish Office
iFOREX Revises Earnings Forecast; AvaTrade to Close Polish Office
iFOREX Revises Earnings Forecast; AvaTrade to Close Polish Office
Today’s financial news recap covers iFOREX cuts its first-half earnings estimate, AvaTrade closes its Poland branch, Devexperts targets South Korean brokers, and TradingView adds MCP for AI tools.
Finance Magnates Daily Recap brings you the latest news from forex and CFD brokers, fintech, payments, cryptocurrency, digital assets, trading platforms, financial regulation and global markets.
Get the key company news, executive moves, deals, regulatory updates and market developments of the day, in just a few minutes. New episodes published every weekday.
Read more: https://www.financemagnates.com
#FinanceMagnates #ForexNews #FintechNews
Today’s financial news recap covers iFOREX cuts its first-half earnings estimate, AvaTrade closes its Poland branch, Devexperts targets South Korean brokers, and TradingView adds MCP for AI tools.
Finance Magnates Daily Recap brings you the latest news from forex and CFD brokers, fintech, payments, cryptocurrency, digital assets, trading platforms, financial regulation and global markets.
Get the key company news, executive moves, deals, regulatory updates and market developments of the day, in just a few minutes. New episodes published every weekday.
Read more: https://www.financemagnates.com
#FinanceMagnates #ForexNews #FintechNews
Today’s financial news recap covers iFOREX cuts its first-half earnings estimate, AvaTrade closes its Poland branch, Devexperts targets South Korean brokers, and TradingView adds MCP for AI tools.
Finance Magnates Daily Recap brings you the latest news from forex and CFD brokers, fintech, payments, cryptocurrency, digital assets, trading platforms, financial regulation and global markets.
Get the key company news, executive moves, deals, regulatory updates and market developments of the day, in just a few minutes. New episodes published every weekday.
Read more: https://www.financemagnates.com
#FinanceMagnates #ForexNews #FintechNews
Today’s financial news recap covers iFOREX cuts its first-half earnings estimate, AvaTrade closes its Poland branch, Devexperts targets South Korean brokers, and TradingView adds MCP for AI tools.
Finance Magnates Daily Recap brings you the latest news from forex and CFD brokers, fintech, payments, cryptocurrency, digital assets, trading platforms, financial regulation and global markets.
Get the key company news, executive moves, deals, regulatory updates and market developments of the day, in just a few minutes. New episodes published every weekday.
Read more: https://www.financemagnates.com
#FinanceMagnates #ForexNews #FintechNews
Today’s financial news recap covers iFOREX cuts its first-half earnings estimate, AvaTrade closes its Poland branch, Devexperts targets South Korean brokers, and TradingView adds MCP for AI tools.
Finance Magnates Daily Recap brings you the latest news from forex and CFD brokers, fintech, payments, cryptocurrency, digital assets, trading platforms, financial regulation and global markets.
Get the key company news, executive moves, deals, regulatory updates and market developments of the day, in just a few minutes. New episodes published every weekday.
Read more: https://www.financemagnates.com
#FinanceMagnates #ForexNews #FintechNews
Today’s financial news recap covers iFOREX cuts its first-half earnings estimate, AvaTrade closes its Poland branch, Devexperts targets South Korean brokers, and TradingView adds MCP for AI tools.
Finance Magnates Daily Recap brings you the latest news from forex and CFD brokers, fintech, payments, cryptocurrency, digital assets, trading platforms, financial regulation and global markets.
Get the key company news, executive moves, deals, regulatory updates and market developments of the day, in just a few minutes. New episodes published every weekday.
Read more: https://www.financemagnates.com
#FinanceMagnates #ForexNews #FintechNews
Can you memorise the textbook? That’s not necessarily the point.
Can you memorise the textbook? That’s not necessarily the point.
Can you memorise the textbook? That’s not necessarily the point.
Can you memorise the textbook? That’s not necessarily the point.
Can you memorise the textbook? That’s not necessarily the point.
Can you memorise the textbook? That’s not necessarily the point.
What matters is whether you can retain the information, understand it and actually apply it.
Take brokerage models. Knowing what a brokerage model is only gets you so far. What companies really need is an understanding of how to build one and how it can be applied.
That kind of practical understanding goes beyond simply reading a textbook.
#FinanceMagnates #FMAcademy #Fintech #FinanceCareers #ProfessionalDevelopment
What matters is whether you can retain the information, understand it and actually apply it.
Take brokerage models. Knowing what a brokerage model is only gets you so far. What companies really need is an understanding of how to build one and how it can be applied.
That kind of practical understanding goes beyond simply reading a textbook.
#FinanceMagnates #FMAcademy #Fintech #FinanceCareers #ProfessionalDevelopment
What matters is whether you can retain the information, understand it and actually apply it.
Take brokerage models. Knowing what a brokerage model is only gets you so far. What companies really need is an understanding of how to build one and how it can be applied.
That kind of practical understanding goes beyond simply reading a textbook.
#FinanceMagnates #FMAcademy #Fintech #FinanceCareers #ProfessionalDevelopment
What matters is whether you can retain the information, understand it and actually apply it.
Take brokerage models. Knowing what a brokerage model is only gets you so far. What companies really need is an understanding of how to build one and how it can be applied.
That kind of practical understanding goes beyond simply reading a textbook.
#FinanceMagnates #FMAcademy #Fintech #FinanceCareers #ProfessionalDevelopment
What matters is whether you can retain the information, understand it and actually apply it.
Take brokerage models. Knowing what a brokerage model is only gets you so far. What companies really need is an understanding of how to build one and how it can be applied.
That kind of practical understanding goes beyond simply reading a textbook.
#FinanceMagnates #FMAcademy #Fintech #FinanceCareers #ProfessionalDevelopment
What matters is whether you can retain the information, understand it and actually apply it.
Take brokerage models. Knowing what a brokerage model is only gets you so far. What companies really need is an understanding of how to build one and how it can be applied.
That kind of practical understanding goes beyond simply reading a textbook.
#FinanceMagnates #FMAcademy #Fintech #FinanceCareers #ProfessionalDevelopment